- Home
- PRAX vs BRKR Comparison
PRAX vs BRKR Comparison
Compare PRAX & BRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRAX | BRKR |
|---|---|---|
| Founded | 2015 | 1960 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8B | 7.3B |
| IPO Year | 2020 | 2000 |
Fundamental Metrics
Financial Performance| Metric | PRAX | BRKR |
|---|---|---|
| Price | $312.49 | $48.33 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 13 |
| Target Price | ★ $397.85 | $51.69 |
| AVG Volume (30 Days) | 616.0K | ★ 2.3M |
| Earning Date | 02-27-2026 | 02-12-2026 |
| Dividend Yield | N/A | ★ 0.41% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $7,463,000.00 | ★ $3,438,900,000.00 |
| Revenue This Year | N/A | $3.58 |
| Revenue Next Year | $14,827.76 | $1.46 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 364.98 | 6.10 |
| 52 Week Low | $26.70 | $28.53 |
| 52 Week High | $326.91 | $61.01 |
Technical Indicators
Market Signals| Indicator | PRAX | BRKR |
|---|---|---|
| Relative Strength Index (RSI) | 66.64 | 48.45 |
| Support Level | $266.93 | $47.84 |
| Resistance Level | $306.16 | $56.22 |
| Average True Range (ATR) | 17.82 | 2.17 |
| MACD | -1.32 | -0.38 |
| Stochastic Oscillator | 78.28 | 16.86 |
Price Performance
Historical ComparisonAbout PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
About BRKR Bruker Corporation
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, applied markets, pharmaceutical, and biotechnology industries. The company operates in segments, namely, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from United States.